Physician profile
Richard Charney
NPI 1194790014
$25,241.08
in general payments reported to CMS, 2019-2025
36 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,466 · 2020: $2,261 · 2021: $3,949 · 2022: $2,889 · 2023: $4,086 · 2024: $2,473 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,676.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $7,169.09 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Medtronic, INC. | $2,709.77 | 2021-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $2,495.20 | 2019-2025 | Jot Dx, Aveir, Merlin@Home |
| Astrazeneca Pharmaceuticals LP | $1,967.27 | 2019-2025 | Farxiga, Brilinta |
| Amgen INC. | $1,441.27 | 2019-2025 | Repatha, Repatha |
| Biotronik INC. | $1,383.65 | 2019-2024 | Biomonitor, Acticor 7 Vr-T Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,038.58 | 2019-2024 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,026.74 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $627.32 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $615.79 | 2019-2020 | |
| Pfizer INC. | $494.51 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $488.22 | 2019-2023 | Leqvio |
| Janssen Scientific Affairs, LLC | $411.11 | 2021-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $376.06 | 2019-2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $324.72 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $322.38 | 2019-2020 | |
| Abiomed | $313.19 | 2019-2023 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $284.68 | 2019-2023 | |
| Edwards Lifesciences Corporation | $278.08 | 2019-2024 | Pascal |
| Inspire Medical Systems, INC. | $256.36 | 2024-2025 | Inspire |
| Shockwave Medical, INC | $188.85 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $187.52 | 2023-2025 | Glidewire, Glidesheath Slender, Metacross Otw |
| Portola Pharmaceuticals, LLC | $140.31 | 2019 | |
| Genzyme Corporation | $125.00 | 2025 | |
| Scpharmaceuticals INC. | $122.14 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $85.42 | 2019-2020 | |
| Philips North America LLC | $72.39 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $69.15 | 2019 | |
| Gilead Sciences, INC. | $62.43 | 2019 | |
| Chiesi USA, INC. | $40.77 | 2021-2025 | Kengreal |
| Cardiva Medical, INC. | $29.47 | 2023 | Cardiva Vascade 5f Vcs |
| Merck Sharp & Dohme LLC | $21.70 | 2022 | |
| Novo Nordisk INC | $21.26 | 2025 | Wegovy |
| Irhythm Technologies, INC. | $20.00 | 2020 | |
| Bardy Diagnostics, INC. | $15.66 | 2020 | |
| Amarin Pharma, INC. | $15.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Charney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.